Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments

Phase 1 Recruiting 10 enrolled Ono Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies

Timeline

Start: 2026-07-07
Primary completion: 2028-02
Completion: 2028-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ripretinib	Small molecule	150 mg	Oral

Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments

Summary

Timeline

Drugs

Indications